Oculis Holding AG (Nasdaq: OCS) completed a financing of approximately $59m, consisting of the issuance of 5,000,000 of its ordinary shares at a purchase price of $11.75 per share.

A prospectus required for the listing on the Nasdaq Iceland Main Market has been approved by the Central Bank of Iceland, Financial Supervision. Oculis’s pipeline includes (i) OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; (ii) OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and (iii) OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

BBA//Fjeldco, Cooley LLP and VISCHER AG served as legal advisors to Oculis in connection with the share placement and the listing. The VISCHER team was led by Matthias Staehelin with Stefan Grieder, Vincent Reardon, Balthasar Müller and Julia Levy (all Corporate/M&A).

Author: Matthias Staehelin